| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Ssang-Goo Cho | Q57190964 |
| Ahmed Abdal Dayem | Q59161846 | ||
| P2093 | author name string | Aram Kim | |
| Kyeongseok Kim | |||
| Soo Bin Lee | |||
| P2860 | cites work | Embryonic stem cell differentiation: emergence of a new era in biology and medicine | Q22065783 |
| Fibroblast growth factor-10 is a mitogen for urothelial cells | Q24292889 | ||
| Complementary and alternative therapies as treatment approaches for interstitial cystitis | Q24548037 | ||
| From interstitial cystitis to chronic pelvic pain | Q24601907 | ||
| Cystoscopy and bladder biopsies in patients with bladder pain syndrome carried out following ESSIC guidelines | Q84467729 | ||
| EAU guidelines on chronic pelvic pain | Q84520820 | ||
| Mast cells | Q84742904 | ||
| YKL‐40 and mast cells are associated with detrusor fibrosis in patients diagnosed with bladder pain syndrome/interstitial cystitis according to the 2008 criteria of the European Society for the Study of Interstitial Cystitis | Q85029171 | ||
| Optimization and scale-up of Wharton's jelly-derived mesenchymal stem cells for clinical applications | Q85110777 | ||
| Melatonin treatment improves adipose-derived mesenchymal stem cell therapy for acute lung ischemia-reperfusion injury | Q85315225 | ||
| Interstitial cystitis is bladder pain syndrome with Hunner's lesion | Q87832515 | ||
| Regenerative medicine in urology | Q88216163 | ||
| Endoscopic Injection of Low Dose Triamcinolone: A Simple, Minimally Invasive, and Effective Therapy for Interstitial Cystitis With Hunner Lesions | Q88757995 | ||
| Considerations on the harvesting site and donor derivation for mesenchymal stem cells-based strategies for diabetes | Q90049975 | ||
| Direct conversion of fibroblasts into urothelial cells that may be recruited to regenerating mucosa of injured urinary bladder | Q90288420 | ||
| Urothelial organoids originating from Cd49fhigh mouse stem cells display Notch-dependent differentiation capacity | Q90339620 | ||
| Concise Review: Mesenchymal Stem Cells Derived from Human Pluripotent Cells, an Unlimited and Quality-Controllable Source for Therapeutic Applications | Q90611488 | ||
| A Randomized, Double-blind, Placebo-controlled Trial of Certolizumab Pegol in Women with Refractory Interstitial Cystitis/Bladder Pain Syndrome | Q90720242 | ||
| Overactive bladder and bladder pain syndrome/interstitial cystitis in primary Sjögren's syndrome patients: A nationwide population-based study | Q91356573 | ||
| Current and Future Directions of Stem Cell Therapy for Bladder Dysfunction | Q91406611 | ||
| Differentiation of Urothelium from Mouse Embryonic Stem Cells in Chemically Defined Conditions | Q91625858 | ||
| Verification of mesenchymal stem cell injection therapy for interstitial cystitis in a rat model | Q91918150 | ||
| Differentiation of human urine-derived stem cells into interstitial cells of Cajal-like cells by exogenous gene modification: A preliminary study | Q91926999 | ||
| Directed differentiation of human induced pluripotent stem cells into mature stratified bladder urothelium | Q92035077 | ||
| Bladder Organoids and Spheroids: Potential Tools for Normal and Diseased Tissue Modelling | Q92176642 | ||
| Pathophysiology of interstitial cystitis | Q92394888 | ||
| N-acetylcysteine prevents bladder tissue fibrosis in a lipopolysaccharide-induced cystitis rat model | Q92427835 | ||
| Mesenchymal stem cell-derived exosomes for clinical use | Q92735596 | ||
| Mesenchymal Stem Cells: Time to Change the Name! | Q47094268 | ||
| Using hair-follicle stem cells for urinary bladder-wall regeneration | Q47279772 | ||
| Urine derived cells are a potential source for urological tissue reconstruction | Q47337447 | ||
| Temporal-spatial protein expression in bladder tissue derived from embryonic stem cells | Q47385173 | ||
| Umbilical cord-derived mesenchymal stem cells alleviated inflammation and inhibited apoptosis in interstitial cystitis via AKT/mTOR signaling pathway | Q47402880 | ||
| Sox17 and beta-catenin cooperate to regulate the transcription of endodermal genes | Q47428400 | ||
| The Therapeutic Effect of Human Embryonic Stem Cell-Derived Multipotent Mesenchymal Stem Cells on Chemical-Induced Cystitis in Rats | Q47547764 | ||
| Transplantation of human adipose-derived mesenchymal stem cells on a bladder acellular matrix for bladder regeneration in a canine model | Q47620871 | ||
| Abnormal expression of molecular markers for bladder impermeability and differentiation in the urothelium of patients with interstitial cystitis. | Q47960362 | ||
| Graft-Versus-Host Disease Amelioration by Human Bone Marrow Mesenchymal Stromal/Stem Cell-Derived Extracellular Vesicles Is Associated with Peripheral Preservation of Naive T Cell Populations. | Q48120041 | ||
| Clinical characteristics differ considerably between phenotypes of bladder pain syndrome/interstitial cystitis | Q48161162 | ||
| Molecular and Cellular Mechanisms Involved in Mesenchymal Stem Cell-Based Therapy of Inflammatory Bowel Diseases. | Q48234353 | ||
| Psychosocial phenotyping in women with interstitial cystitis/painful bladder syndrome: a case control study | Q48382086 | ||
| 'Street ketamine'-associated bladder dysfunction: a report of ten cases. | Q48587605 | ||
| In Vitro Differentiation and Propagation of Urothelium from Pluripotent Stem Cell Lines | Q50182645 | ||
| Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States | Q24603889 | ||
| Cross-talk and sensitization of bladder afferent nerves | Q24647428 | ||
| Update on the Pathology and Diagnosis of Interstitial Cystitis/Bladder Pain Syndrome: A Review | Q26749203 | ||
| Homing and migration of mesenchymal stromal cells: How to improve the efficacy of cell therapy? | Q26750318 | ||
| Stem cell therapy in bladder dysfunction: where are we? And where do we have to go? | Q26862700 | ||
| Diet and its role in interstitial cystitis/bladder pain syndrome (IC/BPS) and comorbid conditions | Q27023120 | ||
| Embryonic stem cell lines derived from human blastocysts | Q27861010 | ||
| Biodistribution, migration and homing of systemically applied mesenchymal stem/stromal cells | Q28069791 | ||
| Pathomechanism of Interstitial Cystitis/Bladder Pain Syndrome and Mapping the Heterogeneity of Disease | Q28079052 | ||
| Generation of germline-competent induced pluripotent stem cells | Q28131699 | ||
| Urinary diversion: ileal conduit to neobladder | Q28208320 | ||
| Role of membrane proteins in permeability barrier function: uroplakin ablation elevates urothelial permeability | Q28506180 | ||
| Generating a non-integrating human induced pluripotent stem cell bank from urine-derived cells | Q28535131 | ||
| Depletion of definitive gut endoderm in Sox17-null mutant mice | Q28586636 | ||
| New agents for the medical treatment of interstitial cystitis | Q32066343 | ||
| Induction of human embryonic and induced pluripotent stem cells into urothelium | Q33551978 | ||
| Therapeutic effect of urine-derived stem cells for protamine/lipopolysaccharide-induced interstitial cystitis in a rat model | Q33651101 | ||
| Urine-derived stem cells for potential use in bladder repair | Q33746467 | ||
| Protein synthesis and secretion in human mesenchymal cells derived from bone marrow, adipose tissue and Wharton's jelly | Q33746687 | ||
| Generation of bladder urothelium from human pluripotent stem cells under chemically defined serum- and feeder-free system | Q33755507 | ||
| PPARgamma: an essential regulator of adipogenesis and modulator of fat cell function | Q33770818 | ||
| Mesenchymal stem cell population derived from human pluripotent stem cells displays potent immunomodulatory and therapeutic properties | Q33861809 | ||
| Bladder afferent hyperexcitability in bladder pain syndrome/interstitial cystitis | Q33870858 | ||
| Cytokine effects on gap junction communication and connexin expression in human bladder smooth muscle cells and suburothelial myofibroblasts | Q33933060 | ||
| A population of progenitor cells in the basal and intermediate layers of the murine bladder urothelium contributes to urothelial development and regeneration | Q33953216 | ||
| All-trans retinoic acid directs urothelial specification of murine embryonic stem cells via GATA4/6 signaling mechanisms | Q33991635 | ||
| A comparison of murine smooth muscle cells generated from embryonic versus induced pluripotent stem cells. | Q34037411 | ||
| Differentiation of human bone marrow mesenchymal stem cells into bladder cells: potential for urological tissue engineering | Q34185927 | ||
| Mast cell involvement in interstitial cystitis: a review of human and experimental evidence | Q34264766 | ||
| Multipotential differentiation of human urine-derived stem cells: potential for therapeutic applications in urology | Q34344233 | ||
| Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices. | Q34422955 | ||
| Bladder cancer cell in co-culture induces human stem cell differentiation to urothelial cells through paracrine FGF10 signaling | Q38261539 | ||
| Urothelial differentiation of human amniotic fluid stem cells by urothelium specific conditioned medium | Q38363661 | ||
| Stress and chronic pelvic pain | Q38368356 | ||
| Human autoimmune diseases: a comprehensive update | Q38554722 | ||
| The Role of Glomerulations in Bladder Pain Syndrome: A Review | Q38576183 | ||
| Clinical Trials With Mesenchymal Stem Cells: An Update. | Q38596084 | ||
| Current and emerging drugs for interstitial cystitis/bladder pain syndrome (IC/BPS). | Q38624933 | ||
| Stem Cell Therapy for Interstitial Cystitis/Bladder Pain Syndrome | Q38674296 | ||
| Investigational drugs for bladder pain syndrome (BPS) / interstitial cystitis (IC). | Q38759710 | ||
| Melatonin as an antioxidant: under promises but over delivers | Q38921589 | ||
| The Challenges of Interstitial Cystitis: Current Status and Future Prospects | Q38939006 | ||
| A Novel View of the Adult Stem Cell Compartment From the Perspective of a Quiescent Population of Very Small Embryonic-Like Stem Cells | Q39069176 | ||
| Urothelial generation and regeneration in development, injury, and cancer. | Q39097235 | ||
| Long-term experience with surgical treatment of selected patients with bladder pain syndrome/interstitial cystitis | Q39250116 | ||
| Therapeutic potential of mesenchymal stem cells for diabetes | Q39455373 | ||
| Melatonin improved rat cardiac mitochondria and survival rate in septic heart injury | Q39483032 | ||
| Hyperplasia as a mechanism for rapid resealing urothelial injuries and maintaining high transepithelial resistance | Q39681310 | ||
| Hair stem cells for bladder regeneration in rats: preliminary results. | Q39764278 | ||
| Bladder Acellular Matrix Grafts Seeded with Adipose-Derived Stem Cells and Incubated Intraperitoneally Promote the Regeneration of Bladder Smooth Muscle and Nerve in a Rat Model of Bladder Augmentation | Q40008220 | ||
| Role of PPARgamma and EGFR signalling in the urothelial terminal differentiation programme | Q40571674 | ||
| Structure, function, and pathology of proteoglycans and glycosaminoglycans in the urinary tract. | Q40661762 | ||
| Melatonin induces gamma-glutamylcysteine synthetase mediated by activator protein-1 in human vascular endothelial cells | Q40924153 | ||
| Formation of asymmetric unit membrane during urothelial differentiation | Q41292198 | ||
| Improved efficacy and in vivo cellular properties of human embryonic stem cell derivative in a preclinical model of bladder pain syndrome | Q41488924 | ||
| Are mast cells still good biomarkers for bladder pain syndrome/interstitial cystitis? | Q41570906 | ||
| Carcinogenesis. The fate of intestinal segments used in urinary reconstruction | Q41656830 | ||
| Human adipose tissue derived stem cells as a source of smooth muscle cells in the regeneration of muscular layer of urinary bladder wall. | Q41989194 | ||
| Targeting afferent hyperexcitability for therapy of the painful bladder syndrome | Q42676259 | ||
| Mindfulness-based stress reduction as a novel treatment for interstitial cystitis/bladder pain syndrome: a randomized controlled trial | Q42705368 | ||
| Direct induction of layered tissues from mouse embryonic stem cells: potential for differentiation into urinary tract tissue | Q42819147 | ||
| Therapeutic time window of mesenchymal stem cells derived from bone marrow after cerebral ischemia. | Q43103917 | ||
| Transdifferentiation of human adipose-derived stem cells into urothelial cells: potential for urinary tract tissue engineering | Q44188201 | ||
| Diabetes-induced changes in glucose synthesis, intracellular glutathione status and hydroxyl free radical generation in rabbit kidney-cortex tubules | Q45054914 | ||
| Altered inducible nitric oxide synthase expression and nitric oxide production in the bladder of cats with feline interstitial cystitis | Q45219194 | ||
| A pilot open label study of Cystoprotek in interstitial cystitis | Q45255510 | ||
| MSC-based product characterization for clinical trials: an FDA perspective | Q45862249 | ||
| Abnormal urinary potassium metabolism in patients with interstitial cystitis. | Q45941906 | ||
| Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment. | Q45971212 | ||
| The prevalence of interstitial cystitis in gynecologic patients with pelvic pain, as detected by intravesical potassium sensitivity. | Q46018445 | ||
| Interstitial cystitis patients' use and rating of complementary and alternative medicine therapies | Q46057716 | ||
| Treatment of refractory interstitial cystitis/painful bladder syndrome with CystoProtek--an oral multi-agent natural supplement | Q46220971 | ||
| Response to: Mesenchymal Stem Cells: Time to Change the Name! | Q46314301 | ||
| The destruction of the lower urinary tract by ketamine abuse: a new syndrome? | Q46445701 | ||
| The natural history of interstitial cystitis: a survey of 374 patients | Q46651823 | ||
| Melatonin treatment further improves adipose-derived mesenchymal stem cell therapy for acute interstitial cystitis in rat. | Q46851041 | ||
| Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment | Q34459826 | ||
| Evaluation of silk biomaterials in combination with extracellular matrix coatings for bladder tissue engineering with primary and pluripotent cells | Q34586792 | ||
| Urinary tract infection and inflammation at onset of interstitial cystitis/painful bladder syndrome | Q34592898 | ||
| Interstitial cystitis/painful bladder syndrome | Q34613030 | ||
| The mast cell in interstitial cystitis: role in pathophysiology and pathogenesis | Q34623214 | ||
| Interstitial cystitis/painful bladder syndrome: symptom recognition is key to early identification, treatment | Q34634094 | ||
| Treatment choice, duration, and cost in patients with interstitial cystitis and painful bladder syndrome | Q34634641 | ||
| Interstitial cystitis and systemic autoimmune diseases | Q34682243 | ||
| Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal | Q34694719 | ||
| Japanese guideline for diagnosis and treatment of interstitial cystitis | Q34914275 | ||
| Uroplakins in urothelial biology, function, and disease | Q34973621 | ||
| Clinical guidelines for interstitial cystitis and hypersensitive bladder syndrome | Q34988451 | ||
| Interstitial cystitis: an unsolved enigma | Q35006808 | ||
| Potential targeting of siglecs, mast cell inhibitory receptors, in interstitial cystitis | Q35112704 | ||
| Restoring barrier function to acid damaged bladder by intravesical chondroitin sulfate. | Q35168298 | ||
| Bone marrow mesenchymal stem cells differentiate into urothelial cells and the implications for reconstructing urinary bladder mucosa | Q35223703 | ||
| Mesenchymal stem cells: from experiment to clinic | Q35240668 | ||
| Experimental autoimmune cystitis: a potential murine model for ulcerative interstitial cystitis | Q35525960 | ||
| Bone marrow derived cells facilitate urinary bladder regeneration by attenuating tissue inflammatory responses | Q35533857 | ||
| Comparison of baseline urological symptoms in men and women in the MAPP research cohort | Q35681130 | ||
| Tissue engineering, stem cells, and cloning: opportunities for regenerative medicine | Q35752252 | ||
| The Role of Genetically Modified Mesenchymal Stem Cells in Urinary Bladder Regeneration | Q35785287 | ||
| Mesenchymal Stem Cell Therapy Alleviates Interstitial Cystitis by Activating Wnt Signaling Pathway | Q35844565 | ||
| Regenerative medicine as applied to general surgery | Q35892487 | ||
| Directed differentiation of embryonic stem cells into bladder tissue | Q36013484 | ||
| Comparative analysis of paracrine factor expression in human adult mesenchymal stem cells derived from bone marrow, adipose, and dermal tissue | Q36138509 | ||
| Interstitial cystitis: a primary care perspective. | Q36240611 | ||
| Comparison of molecular profiles of human mesenchymal stem cells derived from bone marrow, umbilical cord blood, placenta and adipose tissue | Q36393978 | ||
| The management of interstitial cystitis: an update | Q36395031 | ||
| Human Urine-derived Stem Cells Seeded Surface Modified Composite Scaffold Grafts for Bladder Reconstruction in a Rat Model | Q36400508 | ||
| Bladder Smooth Muscle Cells Differentiation from Dental Pulp Stem Cells: Future Potential for Bladder Tissue Engineering | Q36530825 | ||
| The Interstitial Cystitis Data Base Study: concepts and preliminary baseline descriptive statistics | Q36860029 | ||
| A pilot study on intravesical administration of curcumin for cystitis glandularis | Q36907988 | ||
| The role of the bladder surface in interstitial cystitis/painful bladder syndrome. | Q36929070 | ||
| Neuroimmune communication in skin: far from peripheral. | Q37057294 | ||
| Complementary therapies for bladder pain syndrome: a systematic review | Q37099293 | ||
| Mesenchymal stem cells protect against the tissue fibrosis of ketamine-induced cystitis in rat bladder | Q37144581 | ||
| Intestinal adenocarcinoma in an augmented ileocystoplasty | Q37145052 | ||
| CUA guideline: Diagnosis and treatment of interstitial cystitis/bladder pain syndrome | Q37341605 | ||
| Comparison of an interstitial cystitis/bladder pain syndrome clinical cohort with symptomatic community women from the RAND Interstitial Cystitis Epidemiology study | Q37489916 | ||
| The prevalence and overlap of interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome in men: results of the RAND Interstitial Cystitis Epidemiology male study | Q37489944 | ||
| Heparin-binding epidermal growth factor-like growth factor functionally antagonizes interstitial cystitis antiproliferative factor via mitogen-activated protein kinase pathway activation | Q37725051 | ||
| TGF-β/MAPK signaling mediates the effects of bone marrow mesenchymal stem cells on urinary control and interstitial cystitis after urinary bladder transplantation | Q37733006 | ||
| Diagnosis and treatment of interstitial cystitis/painful bladder syndrome: a review | Q37758786 | ||
| Wherefore ketamine? | Q37763464 | ||
| Myofascial pain and pelvic floor dysfunction in patients with interstitial cystitis | Q37803142 | ||
| The role of a leaky epithelium and potassium in the generation of bladder symptoms in interstitial cystitis/overactive bladder, urethral syndrome, prostatitis and gynaecological chronic pelvic pain | Q37822912 | ||
| Interstitial cells of Cajal in the urinary tract. | Q37835072 | ||
| AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome | Q37865879 | ||
| Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC. | Q37875244 | ||
| Melatonin as a natural ally against oxidative stress: a physicochemical examination. | Q37900675 | ||
| Chronic pain: emerging evidence for the involvement of epigenetics | Q37983159 | ||
| A review of the molecular aspects of melatonin's anti-inflammatory actions: recent insights and new perspectives. | Q38020932 | ||
| On the free radical scavenging activities of melatonin's metabolites, AFMK and AMK. | Q38045452 | ||
| Intravesical drug delivery for dysfunctional bladder | Q38075592 | ||
| Paracrine effects and heterogeneity of marrow-derived stem/progenitor cells: relevance for the treatment of respiratory diseases. | Q38104891 | ||
| Intravesical treatment of bladder pain syndrome/interstitial cystitis: from the conventional regimens to the novel botulinum toxin injections | Q38205871 | ||
| ADSC therapy in neurodegenerative disorders. | Q38210872 | ||
| Treating interstitial cystitis/bladder pain syndrome as a chronic disease. | Q38227848 | ||
| Interstitial cystitis: epidemiology, pathophysiology, and clinical presentation | Q38243048 | ||
| Calcium signalling in Cajal-like interstitial cells of the lower urinary tract | Q38249926 | ||
| Hyperexcitability of convergent colon and bladder dorsal root ganglion neurons after colonic inflammation: mechanism for pelvic organ cross-talk | Q50475982 | ||
| A nonhuman primate model for urinary bladder regeneration using autologous sources of bone marrow-derived mesenchymal stem cells. | Q50517263 | ||
| Injection of Dental Pulp Stem Cells Promotes Healing of Damaged Bladder Tissue in a Rat Model of Chemically Induced Cystitis. | Q50980800 | ||
| Novel mouse model of chronic inflammatory and overactive bladder by a single intravesical injection of hydrogen peroxide. | Q51254647 | ||
| The future of pharmacologic treatment for bladder pain syndrome/interstitial cystitis: lessons from a meta-analysis. | Q51673010 | ||
| Lower urinary tract phenotype of experimental autoimmune cystitis in mouse: a potential animal model for interstitial cystitis. | Q51688158 | ||
| Tissue engineering of the urinary bladder: current concepts and future perspectives. | Q51690321 | ||
| Mesenchymal Stem Cells in the Musculoskeletal System: From Animal Models to Human Tissue Regeneration? | Q51761478 | ||
| Stress and symptomatology in patients with interstitial cystitis: a laboratory stress model. | Q51973941 | ||
| Role of neurogenic inflammation in local communication in the visceral mucosa. | Q52340820 | ||
| Pharmacological management of interstitial cystitis /bladder pain syndrome and the role cyclosporine and other immunomodulating drugs play. | Q52633080 | ||
| Mesenchymal Stem Cell Therapy for Ischemic Heart Disease: Systematic Review and Meta-analysis. | Q52730314 | ||
| Establishment of a Novel Autoimmune Experimental Model of Bladder Pain Syndrome/Interstitial Cystitis in C57BL/6 Mice. | Q52902261 | ||
| Bladder wall injection of mesenchymal stem cells ameliorates bladder inflammation, overactivity, and nociception in a chemically induced interstitial cystitis-like rat model. | Q53440920 | ||
| Efficiency of questionnaires used to screen for interstitial cystitis. | Q53593998 | ||
| Urothelial differentiation of human umbilical cord-derived mesenchymal stromal cells in vitro. | Q54028110 | ||
| Modulating bladder neuro-inflammation: RDP58, a novel anti-inflammatory peptide, decreases inflammation and nerve growth factor production in experimental cystitis. | Q54493231 | ||
| Small hypoxia-primed mesenchymal stem cells attenuate graft-versus-host disease. | Q54978470 | ||
| Priming with ceramide-1 phosphate promotes the therapeutic effect of mesenchymal stem/stromal cells on pulmonary artery hypertension. | Q55026503 | ||
| Clinical Application of Mesenchymal Stem Cell-Derived Extracellular Vesicle-Based Therapeutics for Inflammatory Lung Diseases | Q57467367 | ||
| Urothelium with barrier function differentiated from human urine-derived stem cells for potential use in urinary tract reconstruction | Q58590577 | ||
| The Impact of Metallic Nanoparticles on Stem Cell Proliferation and Differentiation | Q59133680 | ||
| Longitudinal intravital imaging of transplanted mesenchymal stem cells elucidates their functional integration and therapeutic potency in an animal model of interstitial cystitis/bladder pain syndrome | Q59795311 | ||
| Wnt-GSK3/-Catenin Regulates the Differentiation of Dental Pulp Stem Cells into Bladder Smooth Muscle Cells | Q64234860 | ||
| Production of Mesenchymal Stem Cells Through Stem Cell Reprogramming | Q64249676 | ||
| Current best practice management of interstitial cystitis/bladder pain syndrome | Q64332501 | ||
| The effect of gastric augmentation on bladder function | Q70683127 | ||
| Antiproliferative activity is present in bladder but not renal pelvic urine from interstitial cystitis patients | Q73007204 | ||
| The interstitial cystitis symptom index and problem index | Q73328704 | ||
| A laboratory stress model for examining stress and symptomatology in interstitial cystitis patients | Q73937312 | ||
| Significance of complications of allergic diseases in young patients with interstitial cystitis | Q79327120 | ||
| Treatment of interstitial cystitis | Q79762514 | ||
| Prevalence of painful bladder symptoms and effect on quality of life in black, Hispanic and white men and women | Q80029131 | ||
| Effect of comestibles on symptoms of interstitial cystitis | Q80326568 | ||
| [Structure and function of suburothelial myofibroblasts in the human urinary bladder under normal and pathological conditions] | Q80606161 | ||
| A fresh look at iPS cells | Q83608099 | ||
| Characterization of urine-derived stem cells obtained from upper urinary tract for use in cell-based urological tissue engineering | Q83934533 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P577 | publication date | 2020-03-12 | |
| P1433 | published in | Journal of Clinical Medicine | Q27724774 |
| P1476 | title | Application of Adult and Pluripotent Stem Cells in Interstitial Cystitis/Bladder Pain Syndrome Therapy: Methods and Perspectives | |
| P478 | volume | 9 |
Search more.